Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.56 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.53 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.53 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.47 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.47 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.47 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.47 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19688352 | 1.00 | EPHX2 (0.58) | EPHX2EPHX1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL5590888 | 1.00 | EPHX2 (0.58) | EPHX2EPHX1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL5590880 | 1.00 | EPHX2 (0.58) | EPHX2EPHX1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL9973081 | 0.89 | CYP2C9 (0.50) | EPHX2EPHX1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL8311723 | 0.88 | EPHX2 (0.44) | EPHX2EPHX1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL21376363 | 0.83 | CYP2C9 (0.56) | EPHX2EPHX1ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL3068813 | 0.83 | EPHX1 (0.76) | EPHX2EPHX1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL3071717 | 0.83 | EPHX2 (0.61) | EPHX2EPHX1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL6234506 | 0.81 | EPHX2 (0.51) | EPHX2EPHX1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL4461499 | 0.81 | EPHX2 (0.59) | EPHX2EPHX1TAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464317-B1 | AMINOSTEROID DERIVATIVES AND PROCESS FOR PRODUCING SAME | UNIV LAVAL (CA) | 2023-04-26 | — | — | EP | disclosed |
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-07 | — | — | US | disclosed |
| US-20210387986-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-16 | — | — | US | disclosed |
| US-11174282-B2 | Aminosteroid derivatives and process for producing same | UNIVERSITé LAVAL (CA) | 2021-11-16 | — | — | US | disclosed |
| WO-2019178248-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-09-19 | — | — | WO | disclosed |
| WO-2017205964-A1 | AMINOSTEROID DERIVATIVES AND PROCESS FOR PRODUCING SAME | UNIVERSITé LAVAL (CA) | 2017-12-07 | — | — | WO | disclosed |
| US-9539274-B2 | Methods, compositions, and formulations for preventing or reducing adverse effects in a patient | PERICOR THERAPEUTICS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9539274-B2 | Methods, compositions, and formulations for preventing or reducing adverse effects in a patient | PERICOR THERAPEUTICS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20150272978-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | PERICOR THERAPEUTICS, INC. | 2015-10-01 | — | — | US | disclosed |
| US-20150272978-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | PERICOR THERAPEUTICS, INC. | 2015-10-01 | — | — | US | disclosed |
| JP-2007014251-A | DNA ASSOCIATED WITH HYDROLYSIS OF NORBORNANE DERIVATIVE | MERCIAN CORP | 2007-01-25 | — | — | JP | disclosed |
| US-20070021351-A1 | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor | SCHERING CORPORATION | 2007-01-25 | — | — | US | disclosed |
| US-20070004635-A1 | Method of treating interferon non-responders using HCV protease inhibitor | SCHERING CORPORATION | 2007-01-04 | — | — | US | disclosed |
| EP-1163194-B1 | SELECTIVE NITROGEN FUNCTIONALISATION OF ORGANIC COMPOUNDS | F2 CHEMICALS LTD (GB) | 2003-04-09 | — | — | EP | disclosed |
| US-6441232-B1 | PREFERENTIAL FLUORINATION | F2 CHEMICALS LTD. (GB) | 2002-08-27 | — | — | US | disclosed |
| EP-1163194-A1 | SELECTIVE NITROGEN FUNCTIONALISATION OF ORGANIC COMPOUNDS | F2 Chemicals Limited (GB) | 2001-12-19 | — | — | EP | disclosed |
| WO-2001053234-A1 | SELECTIVE NITROGEN FUNCTIONALISATION OF ORGANIC COMPOUNDS | F2 CHEMICALS LIMITED (GB) | 2001-07-26 | — | — | WO | disclosed |
| US-5624941-A | Pyrazole derivatives, method of preparing them and pharmaceutical compositions in which they are present | SANOFI (FR) | 1997-04-29 | — | — | US | disclosed |
| EP-0576357-B1 | Pyrazole derivatives, process for their preparation and pharmaceutical compositions containing them | SANOFI SA (FR) | 1997-03-05 | — | — | EP | disclosed |
| EP-0576357-A1 | Pyrazole derivatives, process for their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1993-12-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150272978-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | TNNC1, ASAH2, PGF | EPHX2 332/4885EPHX1 431/4885TAS1R3 4823/4885 |
| US-20070004635-A1 | Method of treating interferon non-responders using HCV protease inhibitor | IFNAR1, IFNG, IRF3 | EPHX2 2887/4885EPHX1 2249/4885TAS1R3 3583/4885 |
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | ITGB1, ITGB2, ITGA2 | EPHX2 1146/4885EPHX1 1194/4885TAS1R3 943/4885 |
| US-20210387986-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | ITGB1, ITGB2, ITGA2 | EPHX2 1146/4885EPHX1 1194/4885TAS1R3 943/4885 |
| US-20070021351-A1 | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor | PYGL, SERPINB1, PREP | EPHX2 3392/4885EPHX1 2276/4885TAS1R3 4640/4885 |
| US-11174282-B2 | Aminosteroid derivatives and process for producing same | HSD17B11, HSD17B7, CYP19A1 | EPHX2 2815/4885EPHX1 2865/4885TAS1R3 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.